<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Life Imaging Fla, Inc.

    Life Imaging Fla, Inc.

    Our mission is to educate and provide an affordable early detection system for the...

    Our mission is to educate and provide an afford...

    Amount Raised:    $32,726.00
    Fundraising Status:    EC
    Filing Type:    CF
    Sophiris Bio, Inc.

    Sophiris Bio, Inc.

    Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...

    Sophiris Bio Inc. is a late-stage biopharmaceut...

    Filing Type:    PU
    Allena Pharmaceuticals, Inc.

    Allena Pharmaceuticals, Inc.

    Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...

    Allena’s lead product candidate, reloxaliase,...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    Accuray Incorporated

    Accuray Incorporated

    Accuray develops, manufactures and sells radiation oncology systems that make canc...

    Accuray develops, manufactures and sells radiat...

    Filing Type:    PU
    TransMedics Group, Inc.

    TransMedics Group, Inc.

    TransMedics is a commercial-stage medical technology company transforming organ tr...

    TransMedics is a commercial-stage medical techn...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    MacroGenics, Inc.

    MacroGenics, Inc.

    MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...

    MacroGenics is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    CytoDyn Inc.

    CytoDyn Inc.

    CytoDyn is a publicly traded late stage biotechnology company developing innovativ...

    CytoDyn is a publicly traded late stage biotech...

    Filing Type:    PU
    Leap Therapeutics, Inc.

    Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...

    Leap Therapeutics (NASDAQ: LPTX) is focused on ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.